These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34396051)

  • 1. AXL Inhibition Represents a Novel Therapeutic Approach in
    Beitzen-Heineke A; Berenbrok N; Waizenegger J; Paesler S; Gensch V; Udonta F; Vargas Delgado ME; Engelmann J; Hoffmann F; Schafhausen P; von Amsberg G; Riecken K; Beumer N; Imbusch CD; Lorens J; Fischer T; Pantel K; Bokemeyer C; Ben-Batalla I; Loges S
    Hemasphere; 2021 Sep; 5(9):e630. PubMed ID: 34396051
    [No Abstract]   [Full Text] [Related]  

  • 2. AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells.
    Pearson S; Blance R; Somervaille TCP; Whetton AD; Pierce A
    Hemasphere; 2019 Jun; 3(3):e233. PubMed ID: 31723838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
    Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
    Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
    Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
    Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.
    Sonbol MB; Firwana B; Zarzour A; Morad M; Rana V; Tiu RV
    Ther Adv Hematol; 2013 Feb; 4(1):15-35. PubMed ID: 23610611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin exerts multitarget antileukemia activity in JAK2
    Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
    Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
    Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms.
    Brkic S; Meyer SC
    Hemasphere; 2021 Jan; 5(1):e516. PubMed ID: 33403355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.
    Gorantla SP; Prince G; Osius J; Dinesh DC; Boddu V; Duyster J; von Bubnoff N
    Front Oncol; 2024; 14():1430833. PubMed ID: 39091915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
    Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
    Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
    Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.